Blog
RSS FeedPosted by Michael Wonder on 05 Apr 2018
Woman with brain tumour wants natural therapies subsidised by PHARMAC
5 April 2018 - In October 2015, Tanya Filia was told she wouldn't make Christmas due to a growing brain ...
Posted by Michael Wonder on 05 Apr 2018
Proposal to list mercaptopurine oral suspension
5 April 2018 - PHARMAC is seeking feedback on a proposal to list mercaptopurine oral solution (Allmercap) 20 mg/mL from ...
Posted by Michael Wonder on 03 Apr 2018
Relief for sufferers of neuroendocrine cancer after PHARMAC funding decision
1 April 2018 - Kiwis living with neuroendocrine cancer say they are relieved after PHARMAC recommended their treatment should be ...
Posted by Michael Wonder on 29 Mar 2018
Decision to list eplerenone for the treatment of heart failure
29 March 2018 - PHARMAC is pleased to announce a decision to fund eplerenone (Inspra), subject to certain clinical criteria ...
Posted by Michael Wonder on 27 Mar 2018
Proposal to fund aflibercept and rivaroxaban
27 March 2018 - PHARMAC is seeking feedback on a proposal to list aflibercept (Eylea) and rivaroxaban (Xarelto) through a ...
Posted by Michael Wonder on 26 Mar 2018
Rejected by the Government, I've spent $160,000 just to keep myself alive
25 March 2018 - Jess Spence currently pays for her Neuroendocrine cancer treatment in Melbourne, Australia. PHARMAC are still to decide ...
Posted by Michael Wonder on 15 Mar 2018
Proposal to fund denosumab for osteoporosis
16 March 2018 - PHARMAC is proposing to fund denosumab (Prolia) injections from 1 June 2018 for the treatment of severe, ...
Posted by Michael Wonder on 15 Mar 2018
Decision to open list montelukast tablets
15 March 2018 - PHARMAC will remove the Special Authority and Hospital Medicine restrictions on montelukast 4 mg, 5 mg ...
Posted by Michael Wonder on 15 Mar 2018
PHARMAC publishes indicative agenda for May 2018 PTAC meeting
15 March 2018 - The May 2018 PTAC meeting will review the following applications for several new medicines. ...
Posted by Michael Wonder on 11 Mar 2018
Proposal to widen access and change the funded brand of tenofovir disoproxil and entecavir
9 March 2018 - PHARMAC is delighted to propose the widening of access to tenofovir disoproxil and entecavir, anti-viral medicines ...
Posted by Michael Wonder on 07 Mar 2018
Cancer sufferers want Oz treatments: 'I want to live'
7 March 2018 - A Tauranga woman with terminal breast cancer has had to fundraise over $100,000 to pay for a ...
Posted by Michael Wonder on 07 Mar 2018
Decision to change the funded brand of aripiprazole and remove listing restrictions
7 March 2018 - PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Limited for ...
Posted by Michael Wonder on 28 Feb 2018
New Zealand Pharmaceutical Schedule - 1 March 2018
1 March 2018 - The March 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Feb 2018
New insights on PHARMAC's tardiness in funding Keytruda for patients with NSCLC
21 February 2018 - The minutes from the November 2017 PTAC meeting note further information from MSD, submitted in response ...
Posted by Michael Wonder on 22 Feb 2018
Minutes from November 2017 PTAC meeting provide interesting insights on Roche's submission for Kadcyla
21 February 2018 - The minutes need to be read carefully as they start with a subcommittee outcome. ...